Ocugen, Inc/OCGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Ocugen, Inc

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Ticker

OCGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Shankar Musunuri

Employees

65

Headquarters

Malvern, United States
Website
ocugen.com

Ocugen, Inc Metrics

BasicAdvanced
$445M
Market cap
-
P/E ratio
-$0.23
EPS
3.58
Beta
-
Dividend rate
$445M
3.58248
$2.11
$0.35
8.9M
1.869
5.066
9.349
-79.01%
-110.32%
-100.56%
63.146
14.712
14.711
140.53%
40.22%
421.25%

What the Analysts think about Ocugen, Inc

Analyst Ratings

Majority rating from 3 analysts.
Buy

Ocugen, Inc Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,190.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
-83.33%
Net income
-$12M
26.60%
Profit margin
-1,190.00%
659.61%

Ocugen, Inc Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 21.05%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.10
-$0.06
-$0.03
-$0.05
-
Expected
-$0.07
-$0.07
-$0.07
-$0.06
-$0.05
Surprise
36.36%
-14.29%
-53.85%
-21.05%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ocugen, Inc stock?

Ocugen, Inc (OCGN) has a market cap of $445M as of June 20, 2024.

What is the P/E ratio for Ocugen, Inc stock?

The price to earnings (P/E) ratio for Ocugen, Inc (OCGN) stock is 0 as of June 20, 2024.

Does Ocugen, Inc stock pay dividends?

No, Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Ocugen, Inc dividend payment date?

Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Ocugen, Inc?

Ocugen, Inc (OCGN) has a beta rating of 3.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Ocugen, Inc stock price target?

The target price for Ocugen, Inc (OCGN) stock is $6.67, which is NaN% below the current price of $. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ocugen, Inc stock

Buy or sell Ocugen, Inc stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing